Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy - Report - MDSpire
Advertisement
Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy
Clinical Report: Pregnancy-Related Breast Cancer in a BRCA1 Variant Patient
Overview
This case study presents a 38-year-old woman with pregnancy-associated breast cancer and a BRCA1 pathogenic variant. The patient underwent individualized management involving surgery and chemotherapy during pregnancy, highlighting the complexities of treatment in this unique population.
Background
Pregnancy-associated breast cancer (PABC) is rare but carries a higher risk of mortality compared to non-pregnancy-associated cases. Patients with hereditary breast and ovarian cancer syndrome (HBOC), particularly those with BRCA1/2 variants, face unique challenges in management due to the implications of their genetic predisposition. Understanding the treatment options and outcomes for these patients is crucial for optimizing care and improving survival rates.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
The patient was diagnosed with luminal B-like, stage IIA breast cancer at 8 weeks of gestation.
BRCA1 genetic testing confirmed a pathogenic variant, influencing treatment decisions.
Left total mastectomy and sentinel lymph node biopsy were performed, followed by chemotherapy during pregnancy.
Adjuvant chemotherapy included doxorubicin and cyclophosphamide during pregnancy, followed by docetaxel postpartum.
Risk-reducing salpingo-oophorectomy and contralateral mastectomy were staged after the patient's delivery.
Clinical Implications
Management of breast cancer in pregnant patients with BRCA1 variants requires careful consideration of both maternal and fetal health. Individualized treatment plans that defer certain surgical interventions until after delivery can optimize outcomes while minimizing risks.
Conclusion
This case underscores the importance of personalized management strategies for pregnant patients with breast cancer and BRCA1 variants, balancing the need for effective cancer treatment with the safety of the fetus.
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
